ERBB2 and breast carcinoma: Nectin-4 expression is also related to shorter disease-free survival and relapse-free survival in luminal A (24) and luminal B human epidermal growth factor receptor 2 (HER2)-negative (25) breast cancers, suggesting that nectin-4 could be a potential prognostic marker and a therapeutic target of breast cancer.